🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Priya Life Science Clinical trial register
TrackersDrugsComparisonsAPI
Trackers› Clinical trials› Harbin
Clinical trial register · China

Clinical Trials in Harbin, 2026

Every study on the ClinicalTrials.gov registry that lists a site in China and is open, about to open, active-but-closed, or enrolling by invitation. Filter it, cite it, and take it away as a file.

Download CSV
Source: ClinicalTrials.gov, U.S. National Library of Medicine. Complete coverage — all 19052 matching records held by the registry are in this view. Synced 22 Sep 2026, 11:10 UTC
19052
Studies in scope
all four open statuses
11786
Recruiting now
open to new participants
2009
Lead sponsors
across recruiting studies
Top sites
Beijing 5484 Shanghai 3827 Guangzhou 3318 Hangzhou 1812 Wuhan 1343
Narrow the registerReset
Recruitment status
Phase
Lead sponsor
Harbin Medical University24 AstraZeneca24 Eli Lilly and Company20 Hoffmann-La Roche16 Bristol-Myers Squibb16
Site location
Beijing5484 Shanghai3827 Guangzhou3318 Hangzhou1812 Wuhan1343
All 613 locations
Target enrolment
to

Trials with a site in Harbin

545 of 19052 studies
Download
Status
Study
Lead sponsor
Phase
Enrol
Chinese sites
Start
Not yet open
An Open-Label Study to Evaluate the Long-Term Safety and Efficacy of ALXN2220 in Adults With Transthyretin Amyloid Cardiomyopathy
NCT07789483Transthyretin Amyloid Cardiomyopathy (ATTR-CM)
Alexion Pharmaceuticals, Inc.
Phase 3
1,180
Beijing, Chongqing, Guangzhou, Guiyang, Harbin, Wuhan, Changsha, Nanjing
2027-11-23
Not yet open
A Study of Orforglipron (LY3502970) in Chinese Participants With Obesity or Overweight and Weight-Related Health Problems
NCT07790861Obesity, Overweight
Eli Lilly and Company
Phase 3
192
Chengdu, Guangzhou, Hangzhou, Harbin, Hefei, Jinan, Luoyang Shi, Nanchang
2026-12
Not yet open
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606Platinum-sensitive Recurrent Ovarian Cancer
Hansoh BioMedical R&D Company
Phase 3
460
Hefei, Beijing, Chongqing, Xiamen, Guangzhou, Shaoguan, Nanning, Harbin
2026-11-01
Not yet open
Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia
NCT07799129Mixed Dyslipidemia
Eddingpharm (Zhuhai) Co., Ltd.
Phase 2
144
Harbin, Zhejiang
2026-11
Not yet open
A Multicenter, Randomized, Open-Label, Positive Controlled Phase III Study to Evaluate the Efficacy and Safety of VSA012 Injection in Participants With Paroxysmal Nocturnal Hemoglobinuria Who Are Naive to Complement Inhibitor Therapy
NCT07816237Paroxysmal Nocturnal Hemoglobinuria, PNH
Bisirna Therapeutics (Suzhou) Co., Ltd.
Phase 3
70
Beijing, Jilin City, Quanzhou, Guangzhou, Nanning, Harbin, Zhengzhou, Wuhan
2026-10-29
Not yet open
A Study Evaluating Safety and Tolerability of Switching From Semaglutide to Zovaglutide in Adults With Obesity (HORIZON-SWITCH-SZ)
NCT07812597Obesity
Beijing QL Biopharmaceutical Co.,Ltd
Phase 2
210
Beijing, Huizhou, Handan, Langfang, Harbin, Nanyang, Yichang, Changde
2026-10-12
Not yet open
JS207 Plus JS007 Versus Toripalimab Plus Bevacizumab as First-Line Treatment for Advanced Liver Cancer
NCT07823348Hepatocellular Carcinoma
Shanghai Junshi Bioscience Co., Ltd.
Phase 3
560
Harbin, Shanghai
2026-10-08
Not yet open
Evaluate the Safety and Efficacy of Combination Therapy With SYS6090 Injection for Hepatocellular Carcinoma
NCT07761286HCC - Hepatocellular Carcinoma
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 1/2
288
Harbin
2026-09-30
Not yet open
Renal Oxygenation-Guided AKI Reduction Trial
NCT07816640Acute Kidney Injury, Hepatectomy
Chinese PLA General Hospital
Not applicable
1,200
Hefei, Beijing, Chongqing, Lanzhou, Guangzhou, Nanning, Shijiazhuang, Harbin
2026-09-20
Not yet open
Endovascular Treatment for Acute Large Vessel Occlusion With Ultra-Large Ischemic Core
NCT07791810AIS, Stroke
First Affiliated Hospital of Harbin Medical University
Not applicable
450
Harbin
2026-09-18
Recruiting
A Study to Evaluate the Efficacy of VVD-133214 in Combination With Pembrolizumab Compared With Pembrolizumab Alone in Participants With Advanced Cancer of the Colon or Rectum
NCT07811193Colorectal Adenocarcinoma
Vividion Therapeutics, Inc.
Phase 2
140
Bengbu, Beijing, Fuzhou, Guangzhou, Harbin, Wuhan, Jinan, Shanghai
2026-09-11
Not yet open
A Trial to Explore the Efficacy and Safety of O-triple as Initial Therapy in the Active Lupus Nephritis Patients (INITIAL Trial)
NCT07767188Lupus Nephritis
Zhao Minghui
Phase 3
70
Fuzhou, Guangzhou, Harbin, Nanjing, Xuzhou, Nanchang, Shenyang, Yantai
2026-09-10
Not yet open
PCSK9 Inhibitor for Intracranial Atherosclerosis Related Acute Ischemic Stroke
NCT07466251Acute Ischemic Stroke AIS, Intracranial Atherosclerosis ICAS, Atherosclerotic Plaque
Peking Union Medical College Hospital
Phase 4
1,212
Beijing, Meizhou, Cangzhou, Qinhuangdao, Shijiazhuang, Tangshan, Harbin, Zhengzhou
2026-09-01
Not yet open
A Study to Learn About the Study Medicine Called PF-08653944 Taken Once-Weekly Compared to Placebo in Chinese Adults With Overweight or Obesity
NCT07792954Obesity, Overweight
Pfizer
Phase 3
300
Hefei, Beijing, Chongqing, Huizhou, Hengshui, Shijiazhuang, Harbin, Luoyang
2026-09-01
Not yet open
A Study of GFH276 Combined With Cetuximab or Chemotherapy in Participants With Solid Tumors and Pancreatic Ductal Adenocarcinoma (PDAC) Harboring RAS Mutation
NCT07678593Advanced Solid Tumors Cancer, Pancreatic Ductal Adenocarcinoma, RAS Mutation
Genfleet Therapeutics (Shanghai) Inc.
Phase 1/2
222
Beijing, Guangzhou, Harbin, Zhengzhou, Wuhan, Shenyang, Xi'an, Jinan
2026-09
Not yet open
Birelentinib Plus R-CHOP in Patients With Newly Diagnosed Diffuse Large B-Cell Lymphoma (TAI-SHAN19)
NCT07712588Diffuse Large B-Cell Lymphoma (DLBCL)
Dizal Pharmaceuticals
Phase 2/3
880
Chongqing, Harbin, Changsha, Jinan, Shanghai
2026-09
Recruiting
Phase II Study of Subretinal JWK001 for Neovascular Age-Related Macular Degeneration
NCT07776522Neovascular Age-Related Macular Degeneration (nAMD) Wet AMD
West China Hospital
Phase 2
50
Beijing, Jilin City, Chongqing, Shantou, Zhejiang, Harbin, Zhengzhou, Wuhan
2026-08-31
Not yet open
A Phase 2 Study of ABSK043 Combined With Osimertinib
NCT07710612Non-Small Cell Lung Cancer With EGFR-mutated and PD-L1 Positive
Abbisko Therapeutics Co, Ltd
Phase 2
72
Guangzhou, Harbin, Wuhan, Shenyang, Shanghai, Taiyuan, Hangzhou
2026-08-31
Recruiting
A Clinical Trial of TQB6426 for Injection in Patients With Advanced Solid Tumors
NCT07730190Advanced Malignancies
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
Phase 1
145
Hefei, Beijing, Fuzhou, Guangzhou, Harbin, Zhengzhou, Changsha, Shanghai
2026-08-25
Not yet open
A Trial of LBL-024 Combined With Platinum-based Chemotherapy for the Treatment of Advanced EP-NEC
NCT07720193Advanced Extrapulmonary Neuroendocrine Carcinoma
Nanjing Leads Biolabs Co.,Ltd
Phase 3
280
Beijing, Fuzhou, Lanzhou, Guangzhou, Nanning, Harbin, Luoyang, Zhengzhou
2026-08-22
Not yet open
Yanlishuang Buccal Dropping Pills for Acute Pharyngitis
NCT07761013Acute Pharyngitis
Beijing University of Chinese Medicine
Not applicable
400
Guangzhou, Guiyang, Harbin, Nanjing, Nanchang, Jinan, Shanghai, Chengdu
2026-08-01
Not yet open
The Efficacy and Safety of Donafenib Plus PD-1/L1 Monoclonal Antibodies Plus TACE or HAIC as First-line Treatment for Unresectable Hepatocellular Carcinoma A Multi-center, Retrospective Clinical Study
NCT07724951Hepatocellular Carcinoma (HCC)
Shanghai Zhongshan Hospital
Observational
400
Guangzhou, Nanning, Harbin, Qingdao, Shanghai, Kunming
2026-07-31
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007Atherosclerosis, Coronary Artery Disease
Beijing Inno Medicine Co., Ltd.
Phase 2
456
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Harbin, Wuhan, Changsha
2026-07-31
Recruiting
A Study of SI-B036 in Patients With Locally Advanced or Metastatic Gastrointestinal Tumors and Other Solid Tumors
NCT07678970Gastrointestinal Tumor, Solid Tumor
Sichuan Baili Pharmaceutical Co., Ltd.
Phase 1
10
Harbin
2026-07-30
Not yet open
Retlirafusp Alfa Combined With Chemotherapy or Fuzuloparib for Triple-Negative Breast Cancer
NCT07752550Triple-Negative Breast Cancer (TNBC)
Harbin Medical University
Phase 2
120
Harbin
2026-07-30
Recruiting
Study of JAB-23E73 in Combination With Chemotherapy in Participants With Metastatic PDAC Harboring KRAS Gene Alterations
NCT07640295Metastatic Pancreatic Ductal Adenocarcinoma
Jacobio Pharmaceuticals Co., Ltd.
Phase 1/2
80
Beijing, Hangzhou, Changsha, Harbin, Nanjing, Shanghai, Taiyuan, Wuhan
2026-07-16
Recruiting
Non-stenting Treatment Strategy for Acute Myocardial Infarction With Non-severe Stenosis(EROSION IV)
NCT07567625Acute Myocardial Infarction (AMI), ST-Segment Elevation Myocardial Infarction(STEMI), Non-ST-Segment Elevation Myocardial Infarction(NSTEMI)
Harbin Medical University
Not applicable
2,000
Harbin, Beijing, Cangzhou, Chengde, Chengdu, Dalian, Daqing, Hunan
2026-07-13
Recruiting
A Study to Investigate ANS02 in Participants With EGFR Mutation-Positive Non-Small Cell Lung Cancer
NCT07538804Non-Small Cell Lung Cancer
Avistone Biotechnology Co., Ltd.
Phase 1/2
294
Guangzhou, Harbin, Zhengzhou, Chengdu
2026-07-10
By invitation
Research Study to Examine Blood Sugar Control, Treatment Satisfaction and Adherence in People With Type 2 Diabetes After Switching From Daily Basal Insulin to Once-weekly Insulin Icodec
NCT07658417Diabetes Mellitus, Type 2
Novo Nordisk A/S
Observational
216
Beijing, Chongqing, Lanzhou, Jiangmen, Langfang, Harbin, Shiyan, Huai'an
2026-07-02
Not yet open
A Clinical Study of TQB2930 Injection and Chemotherapy With or Without Bevacizumab in the Treatment of Advanced Colorectal Cancer
NCT07653685Colorectal Cancer
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
71
Beijing, Lanzhou, Nanning, Zunyi, Harbin, Zhengzhou, Jingzhou, Wuhan
2026-07
Recruiting
An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's Choice in Participants With Platinum Resistant Ovarian Cancer in China
NCT07604766Platinum-resistant Ovarian Cancer
Genmab
Phase 3
82
Changchun, Changsha, Chengdu, Chongqing, Guangzhou, Hangzhou, Harbin, Jinan
2026-06-26
Recruiting
Clinical Effectiveness and Resource Use in End-Stage Renal Disease Patients: Remote Patient Monitoring Across Dialysis Modalities
NCT07781124End Stage Renal Disease (ESRD), Chronic Kidney Disease (CKD)
Vantive Health LLC
Observational
750
Beijing, Chongqing, Guangzhou, Shijiazhuang, Harbin, Zhengzhou, Wuhan, Changsha
2026-06-17
Not yet open
A Clinical Study for the Safety and Efficacy of BL0020 Injection in Combination With Toripalimab Injection in Patients With Recurrent Extensive-Stage Small Cell Lung Cancer
NCT07550842Small Cell Carcinoma of Lung
Shanghai Best-Link Bioscience, LLC
Phase 1
33
Harbin, Zhengzhou, Wuhan, Changzhou, Shenyang, Taizhou, Shanghai
2026-06-16
Not yet open
Crisugabalin in NMOSD Neuropathic Pain: A Randomized, Double-Blind, Placebo-Controlled Exploratory Trial
NCT07699770Neuromyelitis Optica Spectrum Disorders (NMOSD), Neuropathic Pain
Tang-Du Hospital
Phase 4
110
Beijing, Chongqing, Harbin, Hohhot, Changchun, Shenyang, Xi'an, Ürümqi
2026-06-15
Active, closed
Induction Chemoimmunotherapy Followed by Deescalated Definitive Radiotherapy in Head and Neck Cancer
NCT07791602Head and Neck Squamous Cell Carcinoma, Locally Advanced Head and Neck Cancer, HNSCC
Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Phase 2
180
Beijing, Harbin, Shenyang, Taiyuan, Tianjin
2026-06-12
Recruiting
SG301-SC Injection Safety Study in Subjects With Primary ITP Patients
NCT07710248Primary Immune Thrombocytopenia
Hangzhou Sumgen Biotech Co., Ltd.
Phase 2
60
Fuzhou, Guangzhou, Liuzhou, Yulin, Baoding, Chengde, Tangshan, Harbin
2026-06-11
Recruiting
Oral Paclitaxel Plus Fruquintinib Verus Investigator's Choice in Second-Line Advanced Gastric Cancer
NCT07552402Gastric Cancer or Gastroesophageal Junction Adenocarcinoma
Harbin Medical University
Not applicable
150
Shijiazhuang, Harbin, Qiqihar, Baotou, Dalian, Hangzhou
2026-06-10
Active, closed
Low-Dose Radiotherapy With Retlirafusp Alfa and Chemotherapy as Neoadjuvant Therapy for Resectable Locally Advanced Esophageal Squamous Cell Carcinoma
NCT07682376Esophageal Squamous Cell Carcinoma (ESCC)
Harbin Medical University
Phase 2
96
Harbin
2026-06-10
Not yet open
A Study of AK138D1 Alone or in Combination With Ivonescimab in Advanced Breast Cancer
NCT07560124Breast Cancer
Akeso
Phase 1/2
286
Beijing, Harbin, Chengdu
2026-06-06
Not yet open
A Phase II Study of GV20-0251 in Combination With Anti-PD-1 Monoclonal Antibodies in Patients With Unresectable, Locally Advanced, or Metastatic Solid Tumors.
NCT07623642Uterine Cervical Neoplasms, Triple Negative Breast Neoplasms, Prostatic Neoplasms, Squamous Cell Carcinoma of Head and Neck
GV20 Therapeutics
Phase 2
227
Beijing, Harbin
2026-06-02
Recruiting
A Phase I Study of JSKN021 in Advanced Solid Tumors
NCT07617727Advanced Malignant Solid Tumors
Jiangsu Alphamab Biopharmaceuticals Co., Ltd
Phase 1
199
Fuzhou, Nanning, Harbin, Wuhan, Nanjing, Xuzhou, Jining, Shanghai
2026-06-02
Recruiting
Surgery Plus Postoperative Radiotherapy for T4 Sinonasal Adenoid Cystic Carcinoma: A Prospective Observational Study
NCT07652489Adenoid Cystic Carcinoma, Sinonasal Carcinoma
Eye & ENT Hospital of Fudan University
Observational
70
Harbin, Changsha, Shenyang, Shanghai, Xi’an, Wenzhou
2026-06-01
Recruiting
Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients
NCT07663253Multiple Myeloma
Shanghai Zhongshan Hospital
Observational
333
Beijing, Guangzhou, Shenzhen, Naning, Harbin, Zhengzhou, Wuhan, Nanjing
2026-06
Not yet open
Transcranial Focused Ultrasound Neuromodulation for Post-Stroke Motor Dysfunction
NCT07637825Ischemic Stroke
Jiangsu Taizhou People's Hospital
Not applicable
60
Harbin
2026-06
Recruiting
Phase III Study of HRS-7535 for Hypertension With Overweight or Obesity
NCT07528027Hypertension With Overweight or Obesity
Shandong Suncadia Medicine Co., Ltd.
Phase 3
648
Beijing, Harbin
2026-05-29
Active, closed
Long-Course Concurrent Chemoradiotherapy With Adebrelimab and Apatinib as Neoadjuvant Therapy for Locally Advanced/Low-Lying Rectal Cancer Requiring Sphincter Preservation
NCT07687433Rectal Cancer Patients
Harbin Medical University
Phase 2
43
Harbin
2026-05-29
Recruiting
Clinical Studies of TQB2930 Injection for the Treatment of Advanced Solid Tumors
NCT07512583Advanced Solid Tumor
Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.
Phase 1/2
178
Beijing, Harbin, Tianjin
2026-05-27
Active, closed
Short-course Radiotherapy Combined With Retlirafusp Alfa and CAPOX Chemotherapy as Neoadjuvant Therapy for Locally Advanced Rectal Cancer: A Prospective, Single-arm, Phase II Clinical Study
NCT07663071Rectal Cancer Patients
Harbin Medical University
Phase 2
44
Harbin
2026-05-27
Recruiting
A Clinical Study of SYS6023 Combination Therapy for Advanced Breast Cancer
NCT07597629Advanced Breast Cancer
CSPC Megalith Biopharmaceutical Co.,Ltd.
Phase 2
36
Harbin
2026-05-25
Recruiting
A Study of SKB571 in Participants With Gastrointestinal Tumors
NCT07564466Gastrointestinal Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 2
120
Chongqing, Fuzhou, Xiamen, Guangzhou, Nanning, Shijiazhuang, Harbin, Luoyang
2026-05-20
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553Advanced or Unresectable Hepatocellular Carcinoma (HCC)
Huahui Health
Phase 1/2
30
Bengbu, Hefei, Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Zhengzhou
2026-05-19
Active, closed
A Real-world Study of Immunotherapy Combination Regimens for Treating Liver Cancer in Cold Regions
NCT07645209Liver Cancer
Harbin Medical University
Observational
1,000
Harbin
2026-05-13
Recruiting
Start CPAP Therapy in Obstructive Sleep Apnea Patients After Atrial Fibrillation Ablation
NCT07444372Obstructive Sleep Apnea, Sleep Disorder (Disorder), Atrial Fibrillation (AF), Sleep Disordered Breathing (SDB)
Beijing Anzhen Hospital
Not applicable
658
Beijing, Fuzhou, Zhangzhou, Nanning, Langfang, Shijiazhuang, Xingtai, Harbin
2026-05-12
Recruiting
A Research Study to Look at How Well NNC0487-0111 Works Compared to Placebo in People With Heart Failure and Obesity
NCT07567001Obesity, Heart Failure
Novo Nordisk A/S
Phase 3
5,610
Guangzhou, Shijiazhuang, Harbin, Changsha, Baotou, Changzhou, Nanjing, Suzhou
2026-05-11
Recruiting
An Open Label Extension (OLE) Study (Following Completion of CTQJ230A12301) to Evaluate Long-term Safety and Tolerability of Pelacarsen (TQJ230)
NCT07517263Cardiovascular Disease and Lipoprotein(a)
Novartis Pharmaceuticals
Phase 3
5,700
Beijing, Lanzhou, Foshan, Guangzhou, Harbin, Changsha, Baotou, Nanjing
2026-05-11
Recruiting
SAfety and eFfectiveness of cathetER Ablation for Atrial Fibrillation With Intracranial Hemorrhage (SAFER-AF)
NCT07316270AF - Atrial Fibrillation, Intracranial Hemorrhage, Spontaneous
Beijing Anzhen Hospital
Not applicable
646
Hefei, Beijing, Xiamen, Harbin, Changchun, Xi'an
2026-05-06
Recruiting
Single vs. Dual Antiplatelet Therapy in Patients Undergoing Percutaneous Intervention With DCB-only Strategy (KONG-FREEDOM-I)
NCT07587099Coronary Heart Disease (CHD)
Gan Lijun
Not applicable
2,170
Beijing, Haikou, Harbin, Nanchang, Heze, Jinan, Jining, Liaocheng
2026-05-04
Not yet open
Covered vs Bare Metal Stents for Atherosclerotic Renal Artery Stenosis
NCT07566065Atherosclerotic Renal Artery Stenosis, Hypertension, Renal Artery Stenosis
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
150
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Jinan, Qingdao
2026-04-30
Recruiting
A Phase II Study of AMT-676 Combination Therapies in Advanced Colorectal Cancer
NCT07474727Colorectal Cancer
Multitude Therapeutics Inc.
Phase 2
180
Fuzhou, Nanning, Guangzhou, Harbin, Luoyang, Wuhan, Changsha, Shengyang
2026-04-29
Recruiting
A Study to Learn How Well a Combination of Darolutamide and Androgen Deprivation Therapy (ADT) Works as a Treatment Before Surgery for Men Who Have High-risk Localized Prostate Cancer.
NCT07450599High-risk Localized Prostate Cancer
Bayer
Phase 2
250
Hefei, Beijing, Fuzhou, Lanzhou, Guangzhou, Shijiazhuang, Harbin, Zhengzhou
2026-04-27
By invitation
A Coronary Computed Tomography Angiography-guided Intervention for High Risk Cardiovascular Disease Population in Rural China
NCT07416344Coronary Artery Disease
Harbin Medical University
Not applicable
14,980
Daqing, Harbin, Hegang, Jiamusi, Mudanjiang, Qiqihar, Shuangyashan, Suihua
2026-04-27
Not yet open
Phase II Study of HLX43 Monotherapy or Combined With Immune Checkpoint Inhibitors in Patients With Locally Advanced, Recurrent, or Metastatic Triple-negative Breast Cancer.
NCT07487519Breast Cancer (Triple Negative Breast Cancer (TNBC))
Shanghai Henlius Biotech
Phase 2
180
Harbin
2026-04-25
Recruiting
SKB103 for Injection in Advanced Solid Tumors
NCT07459998Advanced Solid Tumors
Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd.
Phase 1/2
277
Harbin, Shanghai
2026-04-23
Recruiting
Ultra-early Identification of Futile Recanalization After Reperfusion Therapy in Acute Ischemic Stroke Based on Cerebral Autoregulation
NCT07556068Acute Ischemic Stroke, Cerebral Autoregulation
Beijing Shijitan Hospital, Capital Medical University
Observational
129
Beijing, Harbin, Dalian, Weifang
2026-04-20
Not yet open
Evaluation of Chiglitazar Sodium With Lifestyle Intervention for Reversing Prediabetes
NCT07558525Prediabetes
Second Xiangya Hospital of Central South University
Not applicable
472
Quanzhou, Guangzhou, Harbin, Luoyang, Wuhan, Changde, Changsha, Loudi
2026-04-18
Recruiting
Medeliver Intracranial Drug Coated Balloon Catheter for Symptomatic Intracranial Atherosclerotic Stenosis
NCT07542938Symptomatic Intracranial Atherosclerotic Stenosis
Xuanwu Hospital, Beijing
Not applicable
264
Beijing, Fuzhou, Shijiazhuang, Harbin, Nanyang, Zhengzhou, Baotou, Xi'an
2026-04-15
Recruiting
DAREON ® -Lung-1: A Study in People With Advanced Small Cell Lung Cancer to Compare Obrixtamig Plus Atezolizumab, Carboplatin, and Etoposide Treatment With Standard Chemoimmunotherapy
NCT07472517Small Cell Lung Cancer (SCLC), Extensive-stage Small Cell Lung Cancer (ES-SCLC)
Boehringer Ingelheim
Phase 3
670
Beijing, Bengbu, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-04-13
Recruiting
Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE)
NCT07428499Hereditary Angioedema (HAE), Hereditary Angioedema - Type 1, Hereditary Angioedema - Type 2, HAE
ADARx Pharmaceuticals, Inc.
Phase 3
90
Beijing, Harbin, Zhengzhou
2026-04-02
Recruiting
Clinical Trials of Benmelstobart Injection Combined With Anlotinib Hydrochloride Capsules in the Treatment of Advanced or Unresectable Alveolar Soft Part Sarcoma
NCT07548177Alveolar Soft Part Sarcoma
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 2
33
Beijing, Chongqing, Guangdong, Harbin, Zhengzhou, Wuhan, Changsha, Changchun
2026-04-02
Recruiting
Osimertinib Induction and Maintenance for Chemo-ineligible Stage III Unresectable EGFR+ NSCLC: Single-arm Study
NCT07295821Lung Cancer
AstraZeneca
Phase 2
60
Beijing, Changchun, Changsha, Chengdu, Foshan, Fuzhou, Guangzhou, Harbin
2026-04-01
Not yet open
FFR-Guided Revascularization in Atherosclerotic Renal Artery Stenosis
NCT07511309Atherosclerotic Renal Artery Stenosis, Fractional Flow Reserve, Optimal Medical Therapy, Stent Implantation
Chinese Academy of Medical Sciences, Fuwai Hospital
Not applicable
300
Guangzhou, Harbin, Zhengzhou, Nanjing, Nanchang, Dalian, Changchun, Jinan
2026-03-31
Recruiting
Remote Ischemic Preconditioning for Aute Type A Aortic Dissection Surgery
NCT07383909Aortic Dissection Type A
Fujian Medical University
Not applicable
1,312
Hefei, Fuzhou, Xiamen, Guangzhou, Harbin, Zhengzhou, Changsha, Dalian
2026-03-29
Recruiting
LY4268989 in Adults With Moderately to Severely Active Ulcerative Colitis
NCT07415044Ulcerative Colitis (UC), Ulcerative Colitis, Active Moderate, Ulcerative Colitis, Active Severe
Eli Lilly and Company
Phase 2
1,431
Binzhou, Changzhou, Chengdu, Chongqing, Foshan, Guangzhou, Harbin, Hefei
2026-03-26
Recruiting
A Study to Evaluate the Safety, Tolerability, and Efficacy of Pumitamig Alone or in Combination With Other Agents in Participants With Advanced Renal Cell Carcinoma (RCC) (ROSETTA RCC-208)
NCT07293351Advanced Renal Cell Carcinoma (RCC)
Bristol-Myers Squibb
Phase 1/2
474
Beijing, Guangzhou, Tianjin, Harbin, Changsha Shi, Nanjing, Shanghai Shi
2026-03-26
Recruiting
DXP-106 in Solid Tumor Patients.
NCT07532018Solid Tumor, Cancer
Singlomics Biopharmaceuticals Zhuhai Co., Ltd.
Phase 1
54
Harbin, Shanghai, Taiyuan, Hangzhou
2026-03-23
Recruiting
A Study to Evaluate the Safety and Tolerability of Pumitamig Alone or In Combination With Ipilimumab in Participants With First-Line Advanced or Unresectable Hepatocellular Carcinoma (HCC) (ROSETTA HCC-206)
NCT07291076Hepatocellular Carcinoma (HCC)
Bristol-Myers Squibb
Phase 1/2
198
Hefei, Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Harbin, Nanyang
2026-03-16
Recruiting
A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Nivolumab in Combination With Chemotherapy in Participants With Previously Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma (ROSETTA Gastric-204)
NCT07221149Untreated Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma
Bristol-Myers Squibb
Phase 2/3
690
Beijing, Fuzhou, Guangzhou, Nanning, Harbin, Weihui, Zhengzhou, Wuhan
2026-03-13
Recruiting
A Study to Evaluate the Efficacy of Pumitamig Versus Pembrolizumab in Participants With Previously Untreated Advanced Non-Small Cell Lung Cancer and PD-L1 ≥ 50%. (ROSETTA Lung-202)
NCT07361510Non-Small Cell Lung Cancer (NSCLC)
Bristol-Myers Squibb
Phase 3
750
Beijing, Fuzhou, Xiamen, Zhangzhou, Guangzhou, Shantou, Nanning, Harbin
2026-03-12
Active, closed
Camrelizumab Plus Risedronate and Chemotherapy for Triple-Negative Breast Cancer: An Exploratory Clinical Study on Mechanisms and Efficacy
NCT07471815Breast Cancer Triple Negative Breast Cancer
Harbin Medical University
Phase 2
30
Harbin
2026-03-04
Not yet open
A Clinical Study Evaluating the Efficacy and Safety of CMS-D001 Tablets in the Treatment of Adult Patients With Moderate to Severe Plaque-type Psoriasis
NCT07432854Moderate to Severe Plaque Psoriasis
Dermavon Holdings Limited
Phase 2/3
540
Bengbu, Wuhu, Guangzhou, Chengde, Handan, Shijiazhuang, Harbin, Nanyang
2026-03-03
Recruiting
A Study of Amivantamab and Olomorasib Combination Therapy in Participants With Metastatic Non-Small Cell Lung Cancer
NCT07227025Carcinoma, Non-Small-Cell Lung
Janssen Research & Development, LLC
Phase 1/2
60
Guangzhou, Harbin, Shanghai
2026-03-03
Recruiting
Impact of Pringle Maneuver on Postoperative Gallbladder Diseases After Hepatectomy
NCT07452848Gallbladder Diseases, Cholelithiasis
West China Hospital
Observational
2,000
Hefei, Chongqing, Guangzhou, Harbin, Wuhan, Nanjing, Tianjin
2026-03-01
Active, closed
RBD5044 in Chinese Participants With Hypertriglyceridemia
NCT07587788Hypertriglyceridemia
Ribotek Biopharmaceuticals (Shandong) Co., Ltd
Phase 2
40
Daqing, Harbin, Luoyang, Jingzhou, Nanyang, Yuncheng, Beijing
2026-02-28
Recruiting
A Clinical Trial on the Efficacy and Safety of TQB6411 for Injection
NCT07367529Advanced Lung Cancer
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Phase 1/2
465
Beijing, Chongqing, Guangzhou, Guanzhou, Zhongshan, Nanning, Cangzhou, Harbin
2026-02-26
Recruiting
A Phase II Clinical Study to Evaluate HLX43 in Combination With Serplulimab in Subjects With Advanced Lung Cancer
NCT07253142Non Small Cell Lung Cancer, Small Cell Lung Cancer
Shanghai Henlius Biotech
Phase 2
120
Hefei, Fu'zhou, Guangzhou, Nanning, Cangzhou, Harbin, Xinxiang, Wuha
2026-02-05
Recruiting
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
NCT07431281Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Esophageal Cancer
AstraZeneca
Phase 3
2,130
Beijing, Changde, Chengdu, Chongqing, Fuzhou, Guangzhou, Hangzhou, Harbin
2026-02-03
Recruiting
Neoadjuvant Therapy Combined With Trastuzumab Rezetecan and Toripalimab for HR+/HER2-low Breast Cancer (NEOTORCH-BREAST 08)
NCT07383818HR Positive/HER2 Low Breast Cancer
First Affiliated Hospital of Zhejiang University
Phase 2
111
Harbin, Hefei, Shanghai, Xi'an, Zhengzhou
2026-02-01
Not yet open
Adebrelimab Combined With Oral Etoposide for Elderly Patients and Patients With Poor Performance Status in Small Cell Lung Cancer: An Exploratory Clinical Study
NCT07398560Small Cell Lung Cancer
The Third Affiliated Hospital of Harbin Medical University
Phase 2
47
Harbin
2026-02-01
Not yet open
A Single-arm, Single-center, Phase II Clinical Study of Aipalolitovorelizumab (QL1706) Combined With Bevacizumab and Standard Chemotherapy as First-line Treatment for MSS/pMMR Metastatic Colorectal Cancer With BRAF V600E Mutation
NCT07229846Colorectal Cancer
Yanqiao Zhang
Phase 2
30
Harbin
2026-02
Recruiting
A Trial of LBL-024 Monotherapy or Combination Drug in Patients With Triple Negative Breast Cancer
NCT07281976Triple Negative Breast Cancer
Nanjing Leads Biolabs Co.,Ltd
Phase 1/2
220
Guangzhou, Harbin, Zhengzhou, Nanjing, Changchun, Shenyang
2026-01-27
Recruiting
Postoperative Radiotherapy for Early-stage Oral Tongue Squamous Cell Carcinoma Patients With Risk Factors: a Prospective, Multicenter, Randomized Controlled, Open-labelled Trial
NCT07402525Oral Tongue Squamous Cell Carcinoma
Second Affiliated Hospital, Zhejiang University, School of Medicine
Not applicable
190
Bengbu, Chaoyang, Fuzhou, Guandong, Harbin, Wuhan, Changsha, Nanchang
2026-01-26
Active, closed
Time-Restricted Eating for Weight-Loss Maintenance
NCT07163455Overweight or Obese Adults
Harbin Medical University
Not applicable
500
Beijing, Chongqing, Shenzhen, Harbin, Xi'an, Qingdao, Weifang, Chengdu
2026-01-26
Recruiting
A Study to Investigate Sonrotoclax (BGB-11417) Plus Zanubrutinib (BGB-3111) Compared With Venetoclax Plus Acalabrutinib in Adults With Previously Untreated Chronic Lymphocytic Leukemia
NCT07277231Chronic Lymphocytic Leukemia
BeOne Medicines
Phase 3
500
Beijing, Chongqing, Fuzhou, Guangzhou, Nanning, Guiyang, Harbin, Zhengzhou
2026-01-22
Recruiting
First in Human Study of SIM0610 in Solid Tumors
NCT07348211Advanced Solid Tumours, Non-Small Cell Lung Cancer, Colorectal Cancer, Head and Neck Squamous Cell Carcinoma
Jiangsu Simcere Pharmaceutical Co., Ltd.
Phase 1
260
Chongqing, Harbin, Shenyang, Jinan, Shanghai
2026-01-19
Recruiting
Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations
NCT07195695Non-small Cell Lung Cancer
Boehringer Ingelheim
Phase 3
400
Beijing, Changchun, Changsha, Chengdu, Guangzhou, Hangzhou, Harbin, Jinan
2026-01-16
Recruiting
A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hypertrophic Cardiomyopathy in China
NCT07361289Hypertrophic Cardiomyopathy
Bristol-Myers Squibb
Observational
500
Beijing, Guangzhou, Jiazhuang, Harbin, Zhengzhou, Suzhou, Changchun, Dalian
2026-01-15
Recruiting
Efficacy and Safety of LX102 Gene Therapy in Patients With Neovascular Age-related Macular Degeneration (nAMD) (STELLAR)
NCT07317934Neovascular Age-Related Macular Degeneration (nAMD), Wet AMD
Innostellar Biotherapeutics Co.,Ltd
Phase 3
388
Hefei, Beijing, Chongqing, Guangzhou, Shantou, Zhongshan, Xingtai, Harbin
2026-01-14
Recruiting
An Open-label, First-in-Human, Dose-Escalation and Dose-Expansion Phase I/II Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Efficacy of SPR1020 in Patients With Advanced Solid Tumors
NCT07359066Advanced Solid Tumors, PARP Inhibitor
Shanghai SciBrunch Therapeutics Co., Ltd.
Phase 1/2
210
Beijing, Harbin
2026-01-08
Not yet open
A Prospective, Multicenter, Open-label, Randomized Clinical Trial to Evaluate the Efficacy, Durability, and Safety of Aflibercept 8mg in Different Treatment Regimens in Chinese Patients With Polypoidal Choroidal Vasculopathy (PCV)
NCT07365371Polypoidal Choroidal Vasculopathy (PCV), Neovascular Age Related Macular Degeneration (AMD)
Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine
Phase 4
174
Beijing, Foshan, Harbin, Zhengzhou, Wuhan, Nanjing, Nanchang, Jilin City
2026-01-01
Not yet open
Critical Illness After Hematopoietic Cell Transplantation
NCT07328724Critical Illness, Ventilated Patients, Hematopoetic Stem Cell Transplantation, Transplant Complication
Peking University People's Hospital
Observational
4,000
Beijing, Chongqing, Hangzhou, Harbin, Tianjin, Wuhan
2026-01-01
Rows per page Showing 1–100 of 545
1 2 3 Next
Cite this view

Priya Life Science (2026). Clinical trial register: studies with a Chinese investigative site, filtered. Derived from ClinicalTrials.gov. Retrieved 24 September 2026. https://priyalifescience.com/clinical-trials-china/city/harbin

Query this register directly
GET /api/trials?country=cn&status=recruiting&format=json Try it now →

About this register

This register is built from ClinicalTrials.gov, the trial registry run by the U.S. National Library of Medicine. It includes every study on the registry that lists at least one investigative site in China and is recruiting, not yet recruiting, active but no longer recruiting, or enrolling by invitation: 19,052 studies in total at the last sync on 22 Sep 2026, 11:10 UTC. The full list can be downloaded as CSV or queried as JSON through the register API.

This page shows the 545 of those studies with a site in Harbin.

How many clinical trials are recruiting in Harbin?

308 of the 545 studies on this page are recruiting new participants as of the 22 Sep 2026, 11:10 UTC sync. A further 60 have not yet opened recruitment, 171 are active but closed to new participants, and 6 are enrolling by invitation only. Eligibility for any study is decided by its study team.

Summary by phase

Studies by phase (Harbin), 545 studies
PhaseStudiesRecruitingShare
Phase 31717331.4%
Phase 21105820.2%
Phase 1/2675212.3%
Not applicable553510.1%
Phase 154429.9%
Observational50299.2%
Phase 42093.7%
Phase 2/31793.1%
Phase EARLY_PHASE1110.2%

Most active sponsors

Lead sponsors with the most studies (Harbin)
Lead sponsorStudiesRecruiting
AstraZeneca246
Harbin Medical University249
Eli Lilly and Company207
Bristol-Myers Squibb1610
Hoffmann-La Roche166
BeOne Medicines1412
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.149
Merck Sharp & Dohme LLC134
Amgen102
Novartis Pharmaceuticals102
Listing here is informational and not medical advice; eligibility is determined by each study team. See also the Ireland, UK, EU, USA and India registers.